Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Environmental, Social, Governance & Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Bone Marrow Conditioning
    • Clinical Trials
    • Illuccix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
    • Investor Centre
    • Financial Reports & Presentations
    • Corporate Governance
    • ASX Announcements
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News & Views

News & Views

News & Views

Telix Pharmaceuticals and partners receive $500K research grant from Government funded Innovative Manufacturing CRC

ASX, News,

Telix and partners receive $500K research grant from Government-funded Innovative Manufacturing CRC to advance manufacturing of novel cancer…

Read more

Business Update : COVID-19

News,

Telix provides an update on the Company’s risk management assessment of the novel coronavirus (COVID-19)…

Read more

Leader in Prostate Cancer Imaging Prof. Frederik L. Giesel Joins Scientific Advisory Board

News,

Telix Pharmaceuticals Limited is pleased to announce that Professor Dr. Frederik L. Giesel, MD, MBA has joined Telix’s Scientific Advisory Board…

Read more

Positive FDA Feedback on NDA Submission Process for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11)

ASX, News,

Telix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its submission of an NDA for…

Read more

Telix Pharmaceuticals Releases Annual Report Year Ending 2019

ASX, News,

Telix Pharmaceuticals Limited Releases Annual Report Year Ending…

Read more

European Leadership Changes and Appointment of VP Sales and Marketing, EMEA

News,

Telix Pharmaceuticals Limited announces that Ms Odile Jaume will be stepping down from her position of Telix EU…

Read more

Telix Supports Molecular Imaging Summer Program at MSKCC

Events, News,

Telix Pharmaceuticals Ltd is pleased to announce our support of the Molecular Imaging Summer Program at…

Read more

Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging

Clinical, News,

Telix Pharmaceuticals Limited is pleased to announce that the FDA has approved the ZIRCON study for American…

Read more

Robyn Jackson, MBA, CNMT Joins Telix Pharmaceuticals US

News,

With over 15 years of hands-on experience in Diagnostic Imaging and Sales, Robyn will be solidifying our presence in the Western US. Robyn has an extensive background in Diagnostic Imaging…

Read more

Anthony Zinno, MBA Joins Telix Pharmaceuticals US

News,

With more than 26 years of operations experience in the healthcare and life sciences field, Tony will be leading the sales organization as Vice President of Commercial Operations. Tony’s success…

Read more
1 … 24 25 26 27 28 … 30

Subscribe

* indicates required
Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings

Recent legislative changes to the Corporations Act 2001 (Cth), which came into effect on 1 April 2022, mean there are new options available to shareholders as to how you elect to receive your communications from Telix. Telix will no longer send shareholders physical meeting documents unless you request a copy to be mailed.

Telix encourages shareholders to provide your email address so we can communicate with you electronically when shareholder notices become available online for such items as meeting documents, dividend statements (if applicable) and annual reports. You can make a standing election to receive some or all of your shareholder communications in physical or electronic form.

To review or update your current communication preference simply logon to our share registry’s website here. You will need your portfolio log in details or your Shareholder Reference Number (SRN) or Holder Identification Number (HIN). Once logged in, select the ‘communications’ tab at the top of the page.

If at any time you require an additional copy of a communication, or you need more information about the options available to you, you may contact Link Market Services via email at LMSComms@linkmarketservices.com.au